CN1924016B - Human tissue factor pathway inhibitory factor mutation gene m2TFPI, recombination carrier and recombination microzyme including the same - Google Patents

Human tissue factor pathway inhibitory factor mutation gene m2TFPI, recombination carrier and recombination microzyme including the same Download PDF

Info

Publication number
CN1924016B
CN1924016B CN 200610015654 CN200610015654A CN1924016B CN 1924016 B CN1924016 B CN 1924016B CN 200610015654 CN200610015654 CN 200610015654 CN 200610015654 A CN200610015654 A CN 200610015654A CN 1924016 B CN1924016 B CN 1924016B
Authority
CN
China
Prior art keywords
tfpi
human tissue
tissue factor
mutation gene
ppic9
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN 200610015654
Other languages
Chinese (zh)
Other versions
CN1924016A (en
Inventor
冷希岗
余波
张海玲
刘兰霞
宋丽萍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Biomedical Engineering of CAMS and PUMC
Original Assignee
Institute of Biomedical Engineering of CAMS and PUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Biomedical Engineering of CAMS and PUMC filed Critical Institute of Biomedical Engineering of CAMS and PUMC
Priority to CN 200610015654 priority Critical patent/CN1924016B/en
Publication of CN1924016A publication Critical patent/CN1924016A/en
Application granted granted Critical
Publication of CN1924016B publication Critical patent/CN1924016B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention discloses a mutation gene m2TFPI of human gene inhibitor factor with restructuring carrier and restructuring yeast, which possesses sequence as SEQ ID No.1, wherein the restructuring carrier connects m2TFPI DNA and pPIC9 carrier in the T4 connecting enzyme through digest segment of XhoI and EcoRI to form m2TFPI-pPIC9.

Description

The m of human tissue factor pathway inhibitory factor mutation gene 2TFPI, the recombinant vectors that comprises this gene and recombination microzyme
Technical field:
The invention belongs to gene engineering technology field, the recombination microzyme and the expressed proteins thereof that relate in particular to the tissue factor approach inhibition factor mutator gene, contain the recombinant vectors of this gene, transform with this carrier.
Background technology:
(Tissue Factor Pathway Inhibitor TFPI) is the important supressor of tissue factor approach to human tissue factor approach inhibition factor, as the physiological inhibitor of TF:FVIIa mixture coagulation process is had the significant effects effect.TFPI can suppress thrombosis and vascular smooth muscle cell proliferation etc., therefore, the generation and the development of vascular restenosis, atherosclerosis and myocardial infarction etc. is had the effect of slowing down.In addition, experimentation on animals proves that human TFPI recombinant protein (hrTFPI) has preventive and therapeutic effect to thrombosis, septic shock, vascular restenosis, endotoxemia and DIC (disseminated inravascular coagulation) etc.Therefore, TFPI has huge pharmaceutical use, has wide practical use clinically.
At present, existing a plurality of companies utilize different expression systems to carry out the preparation of TFPI recombinant protein with the laboratory both at home and abroad, and China Medicine Academy Sciences China Xiehe Medicine University Biology Medicine Engineering Research Institute genetically engineered laboratory goes out lower-cost high specific acitivity TFPI recombinant protein with pichia yeast expression system stably express.
But, because TFPI is removed in circulation of blood fast, need heavy dose (about 20mg/kg/d) just can reach the clinical treatment purpose, medication inconvenience and high expense have greatly limited its application and result of treatment (Palmier MO clinically, Hall LJ, Reisch CM, et al.Clearance of recombinant tissue factor pathway inhibitor (TFPI) in rabbits.Thromb Haemost, 1992.68 (1): 33-36.Warshawsky I, Bu G, Mast A, et al.The carboxy terminus of tissue factor pathway inhibitor is required forinteracting with hepatoma cells in vitro and in vivo.J Clin Invest, 1995.95 (4): 1773-1781.Ho G, Narita M, Broze GJ, Jr., et al.Recombinant full-length tissuefactor pathway inhibitor fails to bind to the cell surface:implications forcatabolism in vitro and in vivo.Blood, 2000.95 (6): 1973-1978.Bai H, Ma D, ZhangYG, et al.Molecular design and characterization of recombinant long half-lifemutants of human tissue factor pathway inhibitor.Thromb Haemost, 2005.93 (6): 1055-1060.).
Therefore prolong the metabolism time of TFPI recombinant protein in circulation of blood, will reduce medical expense greatly, have great importance promoting its application clinically.
Summary of the invention
The objective of the invention is provides a kind of m of human tissue factor pathway inhibitory factor mutation gene for prolonging the TFPI metabolism time of recombinant protein in circulation of blood 2TFPI.
Second purpose of the present invention provides a kind of by the m of human tissue factor pathway inhibitory factor mutation gene 2The TFPI encoded polypeptides.
The 3rd purpose of the present invention provides a kind of m of human tissue factor pathway inhibitory factor mutation gene that includes 2The recombinant vectors of TFPI.
Last purpose of the present invention provides a kind of m of human tissue factor pathway inhibitory factor mutation gene that utilizes 2The recombination microzyme that the recombinant vectors of TFPI transforms.
Technical scheme of the present invention is summarized as follows:
A kind of m of human tissue factor pathway inhibitory factor mutation gene 2TFPI, it has the described nucleotide sequence of SEQ ID No.1 in the sequence table.
A kind of by the m of human tissue factor pathway inhibitory factor mutation gene 2The TFPI encoded polypeptides, it has the described aminoacid sequence of SEQ ID No.2.
A kind of m of human tissue factor pathway inhibitory factor mutation gene that comprises 2The recombinant vectors of TFPI, it is with the m of human tissue factor pathway inhibitory factor mutation gene 2TFPI DNA adds T with the fragment and the pPIC9 carrier of XhoI and EcoRI digestion 4Ligase enzyme carries out ligation, makes m 2TFPI-pPIC9.
A kind of m of human tissue factor pathway inhibitory factor mutation gene that utilizes 2The recombination microzyme that the recombinant vectors of TFPI transforms, it is to contain the m of human tissue factor pathway inhibitory factor mutation gene 2The recombinant vectors of TFPI imports host's Pichia yeast GS115, becomes GS115/m 2TFPI-pPIC9.
The m of human tissue factor pathway inhibitory factor mutation gene among the present invention 2The TFPI characteristics are: carried out the change of partial nucleotide sequence on the basis of the TFPI polynucleotide sequence that other have been reported; The part carboxyl terminal aminoacid sequence of its coding is different with the TFPI of wild-type; Metabolism time ratio wild-type TFPI (mTFPI) in circulation of blood prolongs, and its activity at external, interior inhibition FXa, does not occur obviously weakening with the cooperative ability of heparin.
On the basis that the present invention finishes, can prolong the metabolism time of TFPI recombinant protein in circulation of blood, simultaneously, keep its biological characteristics, as anticoagulant active, with binding ability of heparin etc. as far as possible.Thereby can significantly reduce the administration number of times of TFPI, reduce medical expense, promote the application clinically of TFPI recombinant protein.
Description of drawings
Fig. 1 m 2TFPI-cDNA construction strategy figure;
A kind of m that contains of Fig. 2 2TFPI-cDNA reorganization (clone) carrier and contain the construction strategy figure of the host cell of this recombinant vectors;
Fig. 3 m 2The polyacrylamide gel electrophoresis collection of illustrative plates of TFPI recombinant protein;
Fig. 4 different concns m 2The TFPI recombinant protein is to the restraining effect of FXa;
The different incubation time m of Fig. 5 2TFPI is to the restraining effect of FXa;
The different incubation time m of Fig. 6 2TFPI is to the restraining effect (when heparin sodium exists) of FXa;
Fig. 7 heparin is to m 2The TFPI recombinant protein suppresses the influence of FXa effect;
Fig. 8 different concns heparin is to m 2The TFPI recombinant protein suppresses the influence of FXa;
Fig. 9 m 2The metabolism content specific activity of TFPI recombinant protein in blood plasma.
Embodiment
Prepare a kind of m of human tissue factor pathway inhibitory factor mutation gene of the present invention 2TFPI, recombinant vectors, recombinant host bacterium and recombinant protein mutant m 2The method of TFPI comprises the steps:
1. be template with mTFPI-pPIC9 plasmid DNA (China Medicine Academy Sciences China Xiehe Medicine University Biology Medicine Engineering Research Institute genetically engineered laboratory makes up), suddenly change with the partial dna sequence of PCR method to mTFPI.Reconnect to m on the pPIC9 carrier 2TFPI-pPIC9 also is transformed into intestinal bacteria TB1.
2. extract m 2The TFPI-pPIC9 plasmid DNA, with restriction enzyme with its linearizing after, be transformed among the yeast competent cell GS115 (American I nvitrogen company), obtain recombination microzyme GS115/m 2TFPI-pPIC9.
3. can make TFPI mutator gene (m 2TFPI) cultivate this reorganization bacterium under the condition of Biao Daing, measure the proteic activity of TFPI with substrate color development method; And, prove m through the SDS-PAGE analysis 2TFPI albumen great expression.
4. with after the isotopic labeling, measure TFPI protein mutant (m 2TFPI) metabolism situation in animal body proves TFPI protein mutant m 2The metabolism time ratio wild-type TFPI of TFPI in circulation of blood prolongs.
5. measure TFPI protein mutant m with substrate color development method 2The activity of TFPI proves that its activity compares with wild-type TFPI, occurs obviously reducing.
TFPI mutator gene m 2The TFPI nucleotide sequence is seen SEQ ID No.1.TFPI mutator gene m 2The partial sequence sudden change except that with the mTFPI gene has identical mutational site, has also taken place at its carboxyl terminal in the TFPI genetic comparison of TFPI total length 828bp and other wild-types.
According to nucleotide sequence SEQ ID No.1, infer the m that expresses 2The proteic aminoacid sequence SEQ of TFPI ID No.2.This m 2The aminoacid sequence of TFPI is made up of 276 amino acid, and molecular weight is 42Da.By mTFPI mutator gene (m to the present invention relates to 2TFPI) deduced amino acid and other wild-types TFPI Argine Monohydrochloride sequence compare, the result shows that its carboxyl terminal partial amino-acid series sudden change is (referring to Thomas JG, Roger E, Robin LW, et al.Structureof the human lipoprotein-associated coagulation inhibitor gene.The Journal ofBiological Chemistry.1991.226 (8) 5036-5041.).Thereby make it in basic maintenance biological characteristics, prolonged the blood plasma metabolism time.
Below by embodiment the present invention is further elaborated.It should be understood that described embodiment is only used for explanation rather than restriction the present invention.
The extraction of embodiment 1mTFPI-pPIC9 plasmid DNA
The fresh bacterium liquid of 100ul TB1 (containing the mTFPI-pPIC9 plasmid) is inoculated in the 10ml LB substratum 37 ℃, the 250rpm incubated overnight; Get the triangular flask of 10 250ml, every bottle adds the 100ml substratum, and the above-mentioned bacterium liquid of inoculation 1ml, and 37 ℃, the 250rpm incubated overnight; The centrifuging and taking precipitation with the resuspended precipitation of 120mlGTE damping fluid, and adds 240mg lytic enzyme, concuss mixing, 30 ℃ of water-bath 30min; Add 240ml lysate (0.2N NaOH 1%SDS prepared fresh) and softly put upside down mixing, leave standstill 5min; Potassium acetate solution (the pH5.5 that adds 180ml 5M; The 3M potassium acetate, 2M acetate), put upside down mixing, ice bath 10min.The centrifugal 15min of 8000rpm uses two-layer filtered through gauze, gets supernatant, and adds isopyknic Virahol, and the centrifugal 20min of 8000rpm gets precipitation behind the mixing; With the resuspended precipitation of 4ml TE damping fluid, (phenol: chloroform=24: 1) extracting once for isopyknic phenol-chloroform mixed solution; The 7.5M ammonium acetate solution that adds 1/2 volume, ice bath 20min behind the mixing gets supernatant after centrifugal, adds the ice-cold ethanol of 2.5 times of volumes, and mixing-20 ℃ leaves standstill more than the 2h; The centrifugal 20min of 4000rpm gets precipitation, and resuspended with 0.6mlTNE (STE) damping fluid, adds the RNaseA solution of 10ul 10mg/mi, 37 ℃ of water-bath 30min behind the mixing; Use phenol successively, the phenol-chloroform mixed solution, each extracting of chloroform is once; Add isopyknic PEG solution (13%PEG 8000,0.8M NaCl) mixing, 4 ℃ leave standstill 30min, the centrifugal 20min of 13000rpm, precipitation is dissolved in (Tris-HCl 10mmol/L in an amount of TE damping fluid with ice-cold 70% ethanol rinsing twice, EDTA1mmol/L, pH8.0).
Embodiment 2 makes up and contains TFPI mutator gene (m 2TFPI) carrier
With plasmid DNA mTFPI-pPIC9 (biomedical engineering institute of China Concord Medical Science University of Chinese Academy of Medical Sciences genetically engineered laboratory makes up) is template, with mutant primer m 0(5 ' AAA GGA GGC CTA ATT GAT GAC GAT GAC(AAA ACC AAA AGA) AAAAGAAAG AAG CAG AGA 3 '), 3 ' Aox (5 ' GAC TGG TTC CAATTG ACA AGC 3 '); For positive anti-primer carries out the pcr amplification first time.Through agarose gel electrophoresis, reclaim test kit (Beijing ancient cooking vessel state biotech development center) purified pcr product with dna gel.Being template with plasmid DNA mTFPI-pPIC9 still, is that primer carries out the pcr amplification second time and (sees Fig. 1, m among the figure with above-mentioned PCR product and 5 ' Aox (5 ' GCA AAT GGC ATT CTG ACA TCC 3 ') 0, m 1, m 2Be mutant primer, contain the mutational site.5 ' Aox and 3 ' Aox are the universal primer of yeast expression vector pPIC9.■ represents the mutational site).Use the aforesaid method purified pcr product.With restriction enzyme XhoI and EcoRI incomplete digestion PCR product and pPIC9 carrier, through agarose gel electrophoresis, after above-mentioned test kit recovery, get 200ng pPIC9 and reclaim product, the PCR product that reclaims with 200ng spends the night under 16 ℃ of conditions in 20 μ L linked systems and to carry out ligation.Linked system contains 1ul and connects damping fluid, 1ulT4DNA ligase enzyme, 17ul water.Get and connect product C aCl 2Be transformed among E.coli (intestinal bacteria) TB1, be coated on the LB culture medium flat plate.
Embodiment 3 makes up and identifies recombination microzyme GS115
Get the plasmid DNA (m that 50ug extracts 2TFPI-pPIC9) cut 1 hour with 50u Sac1 enzyme.With plasmid dehydrated alcohol post precipitation, be dissolved in the 20ul sterilized water.Be equipped with the yeast competent cell with the PEG1000 legal system.The 50ug dna direct added still be in the competent cell of freezing state, in 37 ℃ of water-baths 5 minutes, add then 1.2mlPEG solution (40%PEG 1000,0.2M Bicine, pH8.35), 30 ℃ of water-bath 1h.Centrifugal, with 1.5mlNaCl solution (0.15MNaCl, 10mM Bicine, pH8.35) resuspended thalline.Recentrifuge, (0.15M NaCl, 10mMBicine pH8.35) coat RDB and select to hatch 4-6 day (see figure 2) for 30 ℃ on the flat board behind the resuspended thalline with 0.2ml NaCl solution.Select dull and stereotypedly to go up the picking clone and be inoculated in the 10ml YPD substratum from RDB, 30 ℃, 250rpm were cultivated 18-24 hour.Extract pastoris genomic dna with the granulated glass sphere cracking process.Get the 5ul pastoris genomic dna as touching plate, 5`Aox and 3`Aox. are as just, and anti-primer carries out pcr amplification.Agarose gel electrophoresis is analyzed the PCR product, and judges m according to the size of amplified fragments 2Whether the TFPI-pPIC9 plasmid inserts in the yeast host bacterium genome.Screening m 2The recombination microzyme GS115 that the TFPI-pPIC9 plasmid has inserted.
Embodiment 4m 2The abduction delivering of TFPI recombinant protein
Positive colony is inoculated in the 10ml YPD substratum, and 30 ℃ of 250rpm cultivate 18h; Get 100ul bacterium liquid and be inoculated in the 10mlBMGY substratum, 30 ℃ of 250rpm are cultured to OD600 ≈ 3 (about 16-18h); Centrifugal collecting cell is resuspended in the 30ml BMMY substratum.30 ℃ of 250rpm add 100% methyl alcohol to final concentration and are 0.5% and cultivate 36h, and to add methyl alcohol to final concentration every 12h be 0.5%.And get that supernatant carries out the biological activity analysis and the SDS-PAGE electrophoresis (is seen Fig. 3,1. molecular weight of albumen standard 2.mTFPI recombinant protein 3.m among the figure 0TFPI recombinant protein 4.m 1TFPI recombinant protein 5.m 2The blank plasmid albumen of TFPI recombinant protein 6.pPIC9).
Embodiment 5m 2The metabolism in animal body of TFPI recombinant protein
M with purifying 2The TFPI recombinant protein is used 125Behind the I mark, be injected into the SD rat tail vein, in injection back 0.5,1.0,2.0,4.0,6.0,8.0,10.0min from the eye socket venous plexus get blood centrifugal (1000g, 15min) blood plasma, respectively get blood plasma 100ul and carry out 125M is measured in the I radiocounting 2The metabolism content (see Table 1) of TFPI recombinant protein in blood plasma.
Embodiment 6m 2The external determination of activity of TFPI recombinant protein
FXa is made into the solution of 2nM with TBSA (0.5%BSA, 100mM NaCl, 50mM Tris-HCl PH7.8); With pPIC9 (blank), mTFPI (positive control), m 2TFPI is diluted to the 0.5-2.0nM different concns with TBS (100mM NaCl, 50mM Tris-HClPH7.8), gets its each 100ul and mixes with 100ul FXa, places 37 ℃ of water-bath 30min of 96 orifice plates; Add then behind the 15ul 1mM S-2222 mixing in 37 ℃ of water-bath 30min, measure OD with microplate reader therebetween 405Value.Proof is than the TFPI albumen (mTFPI) of wild-type, m 2The TFPI recombinant protein obvious reduction do not occur in external activity, has excellent activity (seeing Fig. 4,5).
Embodiment 7 heparin are to m 2The mensuration of the external activity influence of TFPI recombinant protein
Get 1.0nM pPIC9, mTFPI, m 2Each 100ul of TFPI mixes with 100ul FXa, and to add heparin sodium to final concentration be 0.05-0.5U/ml, 37 ℃ of water-bath 30min; Add then behind the 15ul 1mM S-2222 mixing in 37 ℃ of water-bath 30min, measure OD with microplate reader therebetween 405Value.Proof is than the TFPI albumen (mTFPI) of wild-type, m 2The bonding force of TFPI recombinant protein and heparin does not obviously reduce yet, and heparin still obviously improves m 2The TFPI recombinant protein is to the inhibition ability (seeing Fig. 6-8) of FXa.
Embodiment 8m 2Determination of activity in the TFPI recombinant protein body
24 SD rats (180-220g) are divided into four groups (6 every group) at random, injection mTFPI, m 2TFPI goes into the SD rat tail vein; Before injection, injection afterwards 0.5,1.0,2.0,4.0,6.0,8.0,10.0min gets blood from the eye socket venous plexus; Blood sample is centrifugal, and (1000g 15min) gets blood plasma, measures activity in vivo with the method for said determination external activity.Proof is than the TFPI albumen (mTFPI) of wild-type, m 2Obvious reduction does not appear in TFPI recombinant protein activity in vivo, still keeps the excellent activity (see figure 9) in vivo in the metabolic process.
In the table 1 rat body 125I-rTFPI blood plasma metabolism content (%)
SEQ?ID?No.1828
gattctgagg?aagatgaaga?acacacaatt?atcacagata?cggagttgcc?accactgaaa?60
cttatgcatt?cattttgtgc?attcaaggcg?gatgatggcc?catgtaaagc?aatcatgaaa?120
agatttttct?tcaatatttt?cactcgacag?tgcgaagaat?ttatatatgg?gggatgtgaa?180
ggaaatcaga?atcgatttga?aagtctggaa?gagtgcaaaa?aaatgtgtac?aagagataat?240
gcaaacagga?ttataaagac?aacattgcaa?caagaaaagc?cagatttctg?ctttttggaa?300
gaagatcctg?gaatatgtcg?aggttatatt?accaggtact?tctacaacaa?tcagacaaaa?360
cagtgtgaac?gtttcaagta?tggtggatgc?ctgggcaata?tgaacaattt?tgagacactg?420
gaagaatgca?agaacatttg?tgaagatggt?ccgaatggtt?tccaggtgga?taattatgga?480
acccagctca?atgctgtgaa?taactccctg?actccgcaat?caaccaaggt?tcccagcctt?540
tttgaatttc?acggtccctc?atggtgtctc?actccagcag?acagaggatt?gtgtcgtgcc?600
aatgagaaca?gattctacta?caattcagtc?attgggaaat?gccgcccatt?taagtacagt?660
ggatgtgggg?gaaatgaaaa?caattttact?tccaaacaag?aatgtctgag?ggcatgtaaa?720
aaaggtttca?tccaaagaat?atcaaaagga?ggcctaatta?aaaccagctc?gagctcgagc?780
tcgcagagag?tgaaaatagc?atatgaagaa?atttttgtta?aaaatatg?828
SEQ?ID?No.2
276
AspSerGluGluAsp?GluGluHisThrIle?IleThrAspThrGlu?LeuProProLeuLys
1 5 10 15 20
LeuMetHisSerPhe?CysAlaPheLysAla?AspAspGlyProCys?LysAlaIleMetLys
25 30 35 40
ArgPhePhePheAsn?IlePheThrArgGln?CysGluGluPheIle?TyrGlyGlyCysGlu
45 50 55 60
GlyAsnGlnAsnArg?PheGluSerLeuGlu?GluCysLysLysMet?CysThrArgAspAsn
65 70 75 80
AlaAsnArgIleIle?LysThrThrLeuGln?GlnGluLysProAsp?PheCysPheLeuGlu
85 90 95 100
GluAspProGlyIle?CysArgGlyTyrIle?ThrArgTyrPheTyr?AsnAsnGlnThrLys
105 110 115 120
GlnCysGluArgPhe?LysTyrGlyGlyCys?LeuGlyAsnMetAsn?AsnPheGluThrLeu
125 130 135 140
GluGluCysLysAsn?IleCysGluAspGly?ProAsnGlyPheGln?VlaAspAsnTyrGly
145 150 155 160
ThrGlnLeuAsnAla?VlaAsnAsnSerLeu?ThrProGlnSerThr?LysVlaproSerLeu
165 170 175 180
PheGluPheHisGly?ProSerTrpCysLeu?ThrProAlaAspArg?GlyLeuCysArgAla
185 190 195 200
AsnGluAsnArgPhe?TyrTyrAsnSerVla?IleGlyLysCysArg?ProPheLysTyrSer
205 210 215 220
GlyCysGlyGlyAsn?GluAsnAsnPheThr?SerLysGlnGluCys?LeuArgAlaCysLys
225 230 235 240
LysGlyPheIleGln?ArgIleSerLysGly?GlyLeuIleLysThr?SerSerSerSerSer
245 250 255 260
SerGlnArgVlaLys?IleAlaTyrGluGlu?IlePheVlaLysAsn?Met
265 270 275

Claims (4)

1. m of human tissue factor pathway inhibitory factor mutation gene 2TFPI is characterized in that it is the described nucleotide sequence of SEQ ID No.1 in the sequence table.
2. one kind by the described m of human tissue factor pathway inhibitory factor mutation gene of claim 1 2The TFPI encoded polypeptides is characterized in that it is the described aminoacid sequence of SEQ ID No.2 in the sequence table.
3. one kind comprises the described m of human tissue factor pathway inhibitory factor mutation gene of claim 1 2The recombinant vectors of TFPI, it is with the described m of human tissue factor pathway inhibitory factor mutation gene 2TFPI DNA adds T with the fragment and the pPIC9 carrier of XhoI and EcoRI digestion 4Ligase enzyme carries out ligation, makes m 2TFPI-pPIC9.
4. recombination microzyme that utilizes the described recombinant vectors of claim 3 to transform, it is to contain the m of human tissue factor pathway inhibitory factor mutation gene according to claim 1 2The recombinant vectors of TFPI imports host's Pichia yeast GS115, becomes GS115/m 2TFPI-pPIC9.
CN 200610015654 2006-09-14 2006-09-14 Human tissue factor pathway inhibitory factor mutation gene m2TFPI, recombination carrier and recombination microzyme including the same Expired - Fee Related CN1924016B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 200610015654 CN1924016B (en) 2006-09-14 2006-09-14 Human tissue factor pathway inhibitory factor mutation gene m2TFPI, recombination carrier and recombination microzyme including the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 200610015654 CN1924016B (en) 2006-09-14 2006-09-14 Human tissue factor pathway inhibitory factor mutation gene m2TFPI, recombination carrier and recombination microzyme including the same

Publications (2)

Publication Number Publication Date
CN1924016A CN1924016A (en) 2007-03-07
CN1924016B true CN1924016B (en) 2010-06-16

Family

ID=37816841

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 200610015654 Expired - Fee Related CN1924016B (en) 2006-09-14 2006-09-14 Human tissue factor pathway inhibitory factor mutation gene m2TFPI, recombination carrier and recombination microzyme including the same

Country Status (1)

Country Link
CN (1) CN1924016B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101857877A (en) * 2010-04-29 2010-10-13 中国医学科学院生物医学工程研究所 Retrovirus eukaryotic expression vector containing TFPI (Tissue Factor Pathway Inhibiyor) gene and GFP (Green Fluorescence Protein) gene as well as construction method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1528894A (en) * 2003-09-25 2004-09-15 复旦大学 Long-acting reconbinant tissue factor channel inhibitor and preparing method thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1528894A (en) * 2003-09-25 2004-09-15 复旦大学 Long-acting reconbinant tissue factor channel inhibitor and preparing method thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Zhiyi Ye et al..Structural requirements of human tissue factor pathwayinhibitor(TFPI) and heparin for TFPI-heparin interaction.Thrombosis Research89.1998,89263-270. *
余波等.人类组织因子途径抑制因子的研究进展.国际生物医学工程杂志29 1.2006,29(1),25-28.
余波等.人类组织因子途径抑制因子的研究进展.国际生物医学工程杂志29 1.2006,29(1),25-28. *
白浩.重组人组织因子途径抑制物及其突变体的基因克隆、表达与性质和药效学的初步研究.复旦大学博士学位论文.2004,全文. *

Also Published As

Publication number Publication date
CN1924016A (en) 2007-03-07

Similar Documents

Publication Publication Date Title
CN102573917B (en) Pegylated L-asparaginase
US10918692B2 (en) Use of antimicrobial peptides for treatment of cancer
CA3086902C (en) Compositions and methods of using chondroitinase abci mutants
CN101547935A (en) Interferon alpha mutant and its polyethylene glycol derivative
EP1371373A1 (en) Recombination super compound interferon used as hepatitis b surface antigen and e antigen inhibitor
US10815461B2 (en) Recombinant uricase enzyme
US20090104176A1 (en) Compositions and methods of using chondroitinase abci mutants
CN101514229B (en) Human interferon alpha derivative and polyethylene glycol modified substance thereof
CN1924016B (en) Human tissue factor pathway inhibitory factor mutation gene m2TFPI, recombination carrier and recombination microzyme including the same
US20160289280A1 (en) Fusion protein of recombinant ganoderma immunoregulatory protein and human serum albumin, preparation method thereof, and application thereof
CN102757945B (en) Human urate oxidase protein and preparation method and polyethylene glycol composite thereof
CN100460507C (en) Human tissue factor pathway inhibitory factor mutation gene m0TFPI, recombination carrier and recombination microzyme including the same
CN101280001B (en) Preparation of human SDF-1 alpha, human SDF-1 alpha obtained therefrom and use thereof
CN101671390B (en) Human interferon alpha derivatives and preparation and use of pegylated products thereof
CN107082804A (en) A kind of egg-shaped pompano β thymosin extrasins and its application
CN100451116C (en) Human tissue factor pathway inhibitory factor mutation gene mTFPI, recombination carrier including the same and host cell thereof
CN116200355A (en) Mutant uricase, uric acid specific conjugate, and preparation method and application thereof
CN1920031A (en) Human tissue factor pathway inhibitory factor mutation gene m1TFPI, recombination carrier and recombination microzyme including the same
CN101906162A (en) Polyethylene glycol modified product of fibroblast growth factor-1 and mutant thereof
CN116808067A (en) Application of lambda-carrageenan in resisting African swine fever virus infection
CN107383204A (en) A kind of fusion protein being made up of sheep interleukin 2, sheep interferon gamma and sheep interferon-tau and preparation method thereof
CN107254000A (en) A kind of fusion protein being made up of sheep albumin and sheep interferon gamma and preparation method thereof and a kind of restructuring sheep long-acting interferon γ
BR0208140A (en) Polypeptide, immunotherapeutic agent for the treatment of psoriasis, isolated nucleic acid sequence or complement, single-stranded and double-stranded vectors, isolated nucleic acid sequence or immunogenic variant thereof, methods for the production of polypeptides, and for treatment and clinical remission of psoriasis, and, microbial host cell
CN102558337B (en) Interferon alpha mutant and polyethylene glycol derivative thereof
AU2014200000B2 (en) Compositions and methods of using chondroitinase abci mutants

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100616

Termination date: 20100914